02 January 2022 : Clinical Research
Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France
Antoine Deney1ABCDEF, Vanessa Nader12ABCDEF, Anthony Matta13ABCDE, Romain Itier1CDF, Pauline Fournier1ABCD, Olivier Lairez
1ADF, Nathalie Pizzinat4ACD, Didier Carrié1ACD, Frédéric Boal 4ACD, Michel Galinier 1ACD, Oksana Kunduzova4ACD, Rania Azar2ACD, Jerome Roncalli14ABCDEFG*
DOI: 10.12659/MSM.934804
Med Sci Monit 2022; 28:e934804
Table 6 Characteristics of ischemic heart failure (IHF) group stratified by type of heart failure.
| CAD-populationN=320 | HFpEFN=50 | HFrEFN=270 | P-value | |
|---|---|---|---|---|
| Age | 70.95±10.404 | 74.04±8.949 | 70.38±10.567 | 0.022 |
| Male sex | 269 (84.06%) | 42 (84.00%) | 227 (84.07%) | 0.990 |
| BMI | 26.28±4.86 | 27.39±5.63 | 26.08±4.69 | 0.081 |
| Atrial fibrillation | 95 (29.69%) | 11 (22.00%) | 84 (31.11%) | 0.195 |
| Chronic kidney disease | 182 (56.87%) | 27 (54.00%) | 155 (57.41%) | 0.479 |
| Dyslipidemia | 106 (33.13%) | 25 (50.00%) | 81 (30.00%) | 0.007 |
| Diabetes | 113 (35.31%) | 19 (38.00%) | 94 (34.81%) | 0.729 |
| Hypertension | 198 (66.9%) | 36 (72.00%) | 162 (60.00%) | 0.123 |
| Smoking | 85 (26.56%) | 8 (16.00%) | 77 (28.52%) | 0.053 |
| Family history | 47 (14.69%) | 7 (14.00%) | 40 (14.81%) | 0.840 |
| Valvopathy | 131 (40.93%) | 17 (34.00%) | 114 (42.22%) | 0.305 |
| RVD | 58 (18.13%) | 3 (6.00%) | 55 (20.37%) | 0.1 |
| TAPSE | 17.29±4.47 | 17.88±2.69 | 17.26±4.55 | 0.706 |
| PAPSE | 41.38±14.01 | 39.67±11.11 | 41.41±14.30 | 0.772 |
| Pacemaker | 26 (8.13%) | 8 (12.00%) | 20 (7.41%) | 0.268 |
| Defibrillator | 26 (8.13%) | 1 (2%) | 25 (9.26%) | 0.096 |
| NYHA | ||||
| 1 | 13 (4.06%) | 0 | 13 (4.81%) | 0.339 |
| 2 | 83 (25.94%) | 13 (26.00%) | 70 (25.93%) | |
| 3 | 87 (27.19%) | 14 (28.00%) | 73 (27.04%) | |
| 4 | 25 (7.81%) | 1 (2.00%) | 24 (8.89%) | |
| Systolic blood pressure | 129.77±23.12 | 139.73±21.452 | 127.95±22.99 | 0.003 |
| Diastolic blood pressure | 74.50±14.09 | 73.83±19.76 | 74.62±14.35 | 0.742 |
| Heart rate | 79.25±20.78) | 74.43±19.21 | 80.13±20.97 | 0.110 |
| Troponin | 169.84±652.32 | 72.15±62.86 | 186.97±705.82 | 0.470 |
| NT-ProBNP | 5889.47±8758.00 | 3724.19±6747.79 | 6135.28±9017.84 | 0.127 |
| β-blockers | 194 (60.63%) | 24 (48.00%) | 170 (62.96%) | 0.047 |
| Diuretics | 191 (59.69%) | 29 (58.00%) | 162 (60.00%) | 0.768 |
| Mineralocorticoids | 55 (17.19%) | 7 (14.00%) | 48 (17.78%) | 0.552 |
| ACE/ARA | 175 (54.69%) | 27 (54.00%) | 148 (54.81%) | 0.915 |
| ARNI | 24 (7.50%) | 0 | 24 (8.89%) | 0.016 |
| Ivabradine | 5 (1.56%) | 0 | 5 (1.85%) | 1 |
| SAPT | 128 (40.00%) | 25 (50.00%) | 103 (38.15%) | 0.189 |
| DAPT | 43 (13.44%) | 7 (14.00%) | 36 (13.33%) | 0.958 |
| DOAC+AVK | 1 (0.31%) | 0 | 1 (0.37%) | 1 |
| AAP+OAC | 30 (9.37%) | 5 (10.00%) | 25 (9.26%) | 0.677 |
| β-blockers | 267 (83.43%) | 32 (64.00%) | 235 (87.04%) | <0.05 |
| Diuretics | 245 (76.56%) | 37 (74.00%) | 208 (77.04%) | 0.514 |
| Mineralocorticoids | 117 (36.56%) | 10 (20.00%) | 107 (39.63%) | 0.007 |
| ACE/ARA | 182 (56.87%) | 37 (74.00%) | 145 (53.70%) | 0.011 |
| ARNI | 66 (20.62%) | 1 (2.00%) | 65 (24.07%) | <0.05 |
| Ivabradine | 11 (3.43%) | 1 (2.00%) | 10 (3.70%) | 1 |
| SAPT | 79 (24.69%) | 22 (44.00%) | 57 (21.11%) | 0.001 |
| DAPT | 201 (62.81%) | 27 (54.00%) | 174 (64.44%) | 0.115 |
| DOAC+AVK | 111 (34.69%) | 15 (30.00%) | 96 (35.55%) | 0.398 |
| AAP+OAC | 77 (24.06%) | 9 (18.00%) | 68 (25.18%) | 0.281 |
| BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant. | ||||